Amicogen, Inc.

KOSDAQ:A092040 Stock Report

Market Cap: ₩253.3b

Amicogen Balance Sheet Health

Financial Health criteria checks 1/6

Amicogen has a total shareholder equity of ₩127.2B and total debt of ₩118.8B, which brings its debt-to-equity ratio to 93.4%. Its total assets and total liabilities are ₩273.8B and ₩146.7B respectively.

Key information

93.43%

Debt to equity ratio

₩118.80b

Debt

Interest coverage ration/a
Cash₩17.72b
Equity₩127.15b
Total liabilities₩146.68b
Total assets₩273.84b

Recent financial health updates

Is Amicogen (KOSDAQ:092040) Using Too Much Debt?

Feb 17
Is Amicogen (KOSDAQ:092040) Using Too Much Debt?

Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?

Jun 19
Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?

Is Amicogen (KOSDAQ:092040) A Risky Investment?

Feb 15
Is Amicogen (KOSDAQ:092040) A Risky Investment?

Recent updates

Amicogen, Inc.'s (KOSDAQ:092040) Share Price Is Matching Sentiment Around Its Revenues

May 23
Amicogen, Inc.'s (KOSDAQ:092040) Share Price Is Matching Sentiment Around Its Revenues

Is Amicogen (KOSDAQ:092040) Using Too Much Debt?

Feb 17
Is Amicogen (KOSDAQ:092040) Using Too Much Debt?

Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 35%

Jan 08
Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 35%

Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share Price

Nov 11
Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share Price

Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding

Jun 27
Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding

Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?

Jun 19
Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?

Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%

Mar 21
Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%

With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting

Mar 23
With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting

Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?

Mar 05
Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?

Is Amicogen (KOSDAQ:092040) A Risky Investment?

Feb 15
Is Amicogen (KOSDAQ:092040) A Risky Investment?

What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?

Jan 31
What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?

Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?

Jan 14
Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?

Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?

Dec 30
Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?

Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?

Dec 15
Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?

Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?

Nov 30
Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?

Financial Position Analysis

Short Term Liabilities: A092040's short term assets (₩69.3B) do not cover its short term liabilities (₩78.0B).

Long Term Liabilities: A092040's short term assets (₩69.3B) exceed its long term liabilities (₩68.7B).

Debt to Equity History and Analysis

Debt Level: A092040's net debt to equity ratio (79.5%) is considered high.

Reducing Debt: A092040's debt to equity ratio has increased from 28.4% to 93.4% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A092040 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: A092040 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27.3% each year

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 06:17
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Amicogen, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mujinn LeeCape Investment & Securities Co., Ltd.
So-Eun ChoiLS Securities Co., Ltd.